Findings

What do systematic reviews say?

24 questions · 24 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 29.2%GRADE not reported 0 · 0%Very low 1 · 4.2%Low 6 · 25%Moderate 10 · 41.7%High 0 · 0%

Canakinumab vs placebo or usual care

Time to WHO Clinical Progression Score of level 7 or above

Canakinumab showed no clear difference in time to WHO Clinical Progression Score of level 7 or above compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
HR 0.8 [0.47, 1.36]
1 study · 454 participants
Low

Canakinumab vs placebo or usual care

Time to death

Canakinumab showed no clear difference in time to death compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
HR 0.71 [0.36, 1.43]
2 studies · 499 participants
Low

Canakinumab vs triamcinolone acetonide

Functional disability at 3 months ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Canakinumab vs triamcinolone acetonide

Health‐related quality of life ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found